First Evaluation after Implementation of a Quality Control System for the Second Line Drug Susceptibility Testing of Mycobacterium tuberculosis Joint Efforts in Low and High Incidence Countries

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Hillemann, Doris ^a   Hoffner, Sven ^b   Cirillo, Daniela ^c   Drobniewski, Francis ^d   Richter, Elvira ^a   Rüsch Gerdes, Sabine ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; QUALITY CONTROL;

ANTITUBERCULAR AGENTS; EUROPE; HEALTH PLAN IMPLEMENTATION; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; TUBERCULOSIS;

EID: 84885406757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076765     Document Type: Article

References (22)

1. Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, et al. (2003) Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard. NCCLS 23: M24-A.
2. Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, et al. (2008) Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392.
3. Garrigó M, Aragón LM, Alcaide F, Borrell S, Cardeñosa E, et al. (2007) Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 45: 1766-1770.
4. Pfyffer GE, Palicova F, Rüsch-Gerdes S, (2002) Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J Clin Microbiol 40: 1670-1674.
5. Rüsch-Gerdes S, Domehl C, Nardi G, Gismondo MR, Welscher H-M, et al. (1999) Multicenter evaluation of the mycobacterial growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs. J Clin Microbiol 37: 45-48.
6. Scarparo C, Ricordi P, Ruggiero G, Piccoli P, (2004) Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to Pyrazinamide, Streptomycin, Isoniazid, Rifampin, and Ethambutol and comparison with the radiometric BACTEC 460 method. J Clin Microbiol 42: 1109-1114.
7. World Health Organization (2004) Anti-tuberculosis drug resistance in the World. Report No. 3. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO/HTM/TB/2004.343.
8. Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, et al. (1999) Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 37: 3179-3186.
9. Kruuner A, Yates MD, Drobniewski FA, (2006) Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 44: 811-818.
10. Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S, (2006) Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 44: 688-692.
11. Laszlo A, Rahman M, Raviglione M, Bustreo F, (1997) Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis 1: 231-238.
12. Johansen IS, Larsen AR, Sandven P, Petrini B, Soini H, et al. (2003) Drug susceptibility testing of Mycobacterium tuberculosis to fluoroquinolones: first experience with a quality control panel in the Nordic-Baltic collaboration. Int J Tuberc Lung Dis 7: 899-902.
13. Kent PT, Kubica G, (1985) Public Health Mycobacteriology: A guide for the level III laboratory. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control 1985: 159-184.
14. Canetti G, Fox W, Khomenko, Mahler HT, Menon NK, et al. (1969) Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41: 21-43.
15. Siddiqi SH (1995) BACTEC 460 TB System. Product and procedure manual, revision D. Becton Dickinson Diagnostic System, Sparks, MD.
16. Fattorini L, Iona E, Cirillo D, Migliori GB, Orefici G, et al. (2008) External quality control of Mycobacterium tuberculosis drug susceptibility testing: results of two rounds in endemic countries. Int J Tuberc Lung Dis 12: 214-217.
17. Shulgina MV, Malakhov VN, Hoffner SE, Haile M, Wright A, (2009) Results of the external quality assessment of Mycobacterium tuberculosis drug susceptibility testing in Russia, 2005-2007. Int J Tuberc Lung Dis 13: 1294-1300.
18. Laslo A, Rahman M, Espinal M, Raviglione M, (2002) World Health Organization/International Union Against Tuberculosis and Lung Disease Network of Supranational Reference Laboratories. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing,1994-1998. Int J Tuberc Lung Dis 6: 748-756.
19. Bai G-H, Kim S-J, Chang CL, (2007) Proficiency analysis of drug susceptibility testing by national-level tuberculosis reference laboratories from 1995 to 2003. J Clin Microbiol 45: 3626-3630.
20. Kim SJ, (2005) Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 25: 564-569.
21. Fattorini L, Migliori GB, Cassone A, Mustazzolu A, Piccaro G, et al. (2012) Italian Multicentre Study on Resistance to Antituberculosis Drugs Group. Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy. Eur Respir J 39: 1263-1266.
22. Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, et al. (2012) Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J Clin Microbiol 50: 1233-1239.